GTSM:4743

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oneness Biotech Co., Ltd. operates as a biopharmaceutical company in Taiwan. More Details


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has Oneness Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4743 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 4743's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

7.3%

4743

-1.4%

TW Pharmaceuticals

-0.2%

TW Market


1 Year Return

632.4%

4743

29.9%

TW Pharmaceuticals

28.6%

TW Market

Return vs Industry: 4743 exceeded the TW Pharmaceuticals industry which returned 29.9% over the past year.

Return vs Market: 4743 exceeded the TW Market which returned 28.6% over the past year.


Shareholder returns

4743IndustryMarket
7 Day7.3%-1.4%-0.2%
30 Day-8.4%-10.5%8.8%
90 Day-37.8%-20.2%20.6%
1 Year632.4%632.4%32.1%29.9%33.1%28.6%
3 Year888.4%888.4%37.7%30.3%55.3%37.8%
5 Year537.3%537.3%22.1%11.8%135.7%94.2%

Long-Term Price Volatility Vs. Market

How volatile is Oneness Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oneness Biotech undervalued compared to its fair value and its price relative to the market?

483.31x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4743's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4743's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4743 is poor value based on its PE Ratio (483.3x) compared to the TW Pharmaceuticals industry average (17.6x).

PE vs Market: 4743 is poor value based on its PE Ratio (483.3x) compared to the TW market (18.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4743's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4743 is overvalued based on its PB Ratio (8.2x) compared to the TW Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is Oneness Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oneness Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Oneness Biotech performed over the past 5 years?

-17.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4743 has high quality earnings.

Growing Profit Margin: 4743 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 4743 has become profitable over the past 5 years, growing earnings by -17.4% per year.

Accelerating Growth: 4743 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 4743 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).


Return on Equity

High ROE: 4743's Return on Equity (1.6%) is considered low.


Next Steps

Financial Health

How is Oneness Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 4743's short term assets (NT$4.0B) exceed its short term liabilities (NT$157.0M).

Long Term Liabilities: 4743's short term assets (NT$4.0B) exceed its long term liabilities (NT$1.4B).


Debt to Equity History and Analysis

Debt Level: 4743 is debt free.

Reducing Debt: 4743 has not had any debt for past 5 years.

Debt Coverage: 4743 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4743 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Oneness Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4743's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4743's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4743's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4743's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 4743 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4743's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Oneness Biotech has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.4%.


Top Shareholders

Company Information

Oneness Biotech Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oneness Biotech Co., Ltd.
  • Ticker: 4743
  • Exchange: GTSM
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$79.521b
  • Shares outstanding: 372.47m
  • Website: https://www.onenessbio.com.tw

Number of Employees


Location

  • Oneness Biotech Co., Ltd.
  • No.236, Xinyi Road
  • 11th Floor
  • Taipei
  • 106
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4743GTSM (Taipei Exchange)YesCommon StockTWTWDJun 2009
6ZDDB (Deutsche Boerse AG)GD EACH REP 5 ORD TWD10REGSDEEURNov 2020

Biography

Oneness Biotech Co., Ltd. operates as a biopharmaceutical company in Taiwan. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 17:23
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.